zintick
BHC Bausch Health Companies+28.8%Stock moveEarnings and guidance

Bausch Health Stock Jumps 29% on Thursday After Raising 2026 Guidance With Q3 Results

The company reported third-quarter revenue of $2.94 billion, up 10%, and raised full-year 2026 revenue, Adjusted EBITDA and Adjusted Cash Flows from Operations guidance.

By Zintick Team · Editor: Kratik Mehta
Published

African woman as a researcher works on the microscope in a laboratory on Covid-19 vaccine for coronavirus pandemic
Photo: True Touch Lifestyle/Shutterstock.com

Key points

  • Shares rose 28.8% Thursday, Oct. 29, 2026, closing at $8.91 after the company raised 2026 guidance with Q3 results
  • Q3 revenue was $2.94 billion, up 10%; GAAP net income attributable to Bausch Health was $436 million
  • Bausch Health excluding Bausch + Lomb posted its first quarter with Adjusted EBITDA above $1 billion
  • The company reduced net debt by more than $500 million in the quarter and authorized a $50 million buyback

Bausch Health (NYSE: BHC) shares rose 28.8% on Thursday, Oct. 29, 2026, closing at $8.91 after a previous close of $6.92, while the S&P 500 ETF (SPY) fell 0.38% that session. Trading volume ran at about 11.4 times its usual level.

The move followed the company's third-quarter results, which it released in an 8-K filed Oct. 28, 2026. The press release attached to that filing reported consolidated revenue of $2.94 billion, up 10% from a year earlier and up 8% on an organic basis, along with GAAP net income attributable to Bausch Health of $436 million, or $1.15 per diluted share.

Guidance raised for Bausch Health excluding Bausch + Lomb

The company raised its full-year 2026 revenue, Adjusted EBITDA and Adjusted Cash Flows from Operations guidance for Bausch Health excluding Bausch + Lomb. Consolidated revenue guidance is $10.975 billion to $11.175 billion, and Bausch Health excluding Bausch + Lomb Adjusted EBITDA guidance is $3.225 billion to $3.275 billion. Management said it had reached more than $1 billion of quarterly Adjusted EBITDA excluding Bausch + Lomb for the first time.

Debt reduction and buyback

The press release said the company reduced net debt by more than $500 million during the quarter. Cash and cash equivalents stood at $2.49 billion as of Sept. 30, 2026, up from $1.31 billion at the end of 2025. The board also authorized a $50 million share repurchase program, which the company said is aimed mainly at offsetting dilution from management equity awards expected to vest in 2027.

Sources

Written with AI from SEC filings and market data, and checked against those sources before publishing. Our editorial standards.

BHC page →

Filings, figures and price history are on the Bausch Health Companies page.